Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical composition for the inhibition of tumorigenesis comprising a pharmaceutical carrier and an antisense nucleic acid comprising at least 100 nucleotides hybridizable in a cell to at least a portion of an RNA transcript of a Nr-CAM gene of SEQ ID NO: 1 in an amount effective to inhibit tumorigenesis by inhibiting hyperproliferation of a human tumor cell having high Nr-CAM expression, wherein said composition is formulated for pharmaceutical use in humans.

2. (Canceled)

3. (Currently amended) A method of inhibiting proliferation of a human tumor cell overexpressing Nr-CAM in a subject comprising administering locally to the subject, at the site or former site of the tumor, ~~an effective amount of~~ a Nr-CAM antisense nucleic acid comprising the complement of nucleotides 119 to 1434 of SEQ ID NO.: 1; wherein the tumor cell comprises a glioblastoma, a glioma, an astrocytoma, or an oligodendroglioma, and wherein the Nr-CAM antisense nucleic acid is administered in an amount effective to inhibit tumorigenesis by inhibiting proliferation of a human tumor cell having high Nr-CAM expression.

4. (Canceled)

5. (Canceled)

6. (Original) The method according to claim 3 in which the subject is a human.

7. (Canceled)

8. (Previously presented) The method according to claim 3 in which the glioblastoma is glioblastoma multiforme.

9-21. (Canceled)

22. (Previously presented) The composition of claim 1, wherein the composition is formulated as a liquid.

23. (Canceled)

24. (Previously presented) The method of claim 3, wherein the local administration is by direct injection.

25. (Previously presented) The method of claim 24, wherein the Nr-CAM antisense nucleic acid is administered locally by direct injection at the site or former site of the tumor.

26. (Previously presented) The method of claim 25, wherein the administration is intratumoral.

27-33. (Canceled)

34. (Previously presented) The composition of claim 1, wherein the antisense nucleic acid comprises the complement of nucleotides 119 to 1434 of SEQ ID NO: 1.

35. (Previously presented) The composition of claim 1, wherein the antisense nucleic acid comprises the complement of nucleotides 1410 to 2746 of SEQ ID NO: 1.